Functional outcomes of GreenLight 180-W photoselective vaporization in patients with large (≥ 80cc) prostates: an analysis of over 3000 men in the Global Greenlight Group (GGG) database.

Abstract

GreenLight photoselective vaporization of the prostate (PVP) has gained widespread adoption as an option to traditional transurethral resection of the prostate. Prior reports expressed concern with the use of PVP in large prostates.The aim of this study was to investigate the adjusted outcomes of GreenLight PVP in men with large (≥ 80cc) vs. small prostates (< 80cc). Data were obtained from the Global Greenlight Group which pools data from 7 high volume centers. Men with established benign prostatic hyperplasia who underwent GreenLight PVP using the XPS-180W system between 2011 and 2019 were eligible and assigned into two groups based on their prostate size (≥ 80 and < 80cc). 11 functional and perioperative covariates were collected.Analyses were adjusted for patient age and presence of median lobe. 3426 men met the inclusion criteria. 34.6% (n = 1187) of patients had a large prostate size. Baseline age and prostate volume were significantly different between the groups.The magnitude of absolute improvement in unadjusted international prostate symptom score was significantly greater in the large (≥ 80cc) prostate group at 12months, with an absolute change of 19.17 points (95% CI 18.46-19.88; p < 0.01). There was also a significant drop in PVR at both 6- (p = 0.007) and 12months (p = 0.005).Therewere no significant differences in transfusion (p = 0.42), hematuria (p = 0.80), or 30-day readmission rates (p = 0.28). Greenlight PVP is a safe and effective alternative for patients with prostate sizes ≥ 80cc, with durable outcomes relatively independent from prostate size.